(Q43868794)

27 November 2017

Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease (English)

1 reference

27 November 2017

0 references

Haruo Hanyu

1

1 reference

27 November 2017

Yuriko Tanaka

2

1 reference

27 November 2017

Hirofumi Sakurai

3

1 reference

27 November 2017

Masaru Takasaki

4

1 reference

27 November 2017

Kimihiko Abe

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

319

1 reference

27 November 2017

1

1 reference

27 November 2017

33-36

1 reference

The cholinergic hypothesis of geriatric memory dysfunction

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Selective loss of central cholinergic neurons in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

1 reference

7 January 2021

The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

A new clinical scale for the staging of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Donepezil for behavioural disorders associated with Lewy bodies: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Lewy bodies and response to tacrine in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Necropsy evidence of central cholinergic deficits in senile dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2801%2902507-1

7 January 2021

10.1016/S0304-3940(01)02507-1

Identifiers

DOI

1 reference

27 November 2017

1 reference